Future of Inhaler Corticosteroid Device Market: Size, Share & Forecasts to 2029

Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.

What Is the Projected Market Size Valuation of the Inhaler Corticosteroid Device Market by 2025?
The market size for inhaler corticosteroid devices has seen robust growth in recent times. It is predicted to rise from $15.75 billion in 2024 to $16.83 billion in 2025, experiencing a compound annual growth rate (CAGR) of 6.9%. Factors contributing to growth during the historic period include enhanced healthcare spending, rising elderly population, favourable government regulations, relentless research and development efforts, and elevated disposable income.

What Is the Estimated Market Growth Value for the Inhaler Corticosteroid Device Industry in 2029?
In the coming years, the inhaler corticosteroid device market is anticipated to experience robust growth, reaching a market size of $21.77 billion in 2029, increasing at a compound annual growth rate (CAGR) of 6.6%. This projected growth within the forecast period is due to factors such as increased occurrence of respiratory conditions, heightened consciousness about respiratory health, substantial funding in respiratory technologies, sharpened focus on health enlightenment, and escalating smoking addiction. Key trends for this forecast period encompass the integration of sophisticated technologies, the formulation of combined treatments, the advent of digital inhalers delivering real-time data, advances in inhaler technology, and the application of data analysis in inhaler devices.

Explore The Complete Report Now:
https://www.thebusinessresearchcompany.com/report/inhaler-corticosteroid-device-global-market-report

What Are the Growth Drivers and Opportunities in the Inhaler Corticosteroid Device Market?
The inhaler corticosteroid device market is projected to grow due to the rising incidence of respiratory diseases. These diseases encompass a variety of conditions that affect lungs and airways, consequently causing issues in breathing efficiently and effectively. Respiratory diseases are on the rise due to increased air pollution, exposing people to harmful particles that result in lung damage and stimulate chronic conditions like asthma and bronchitis. Inhaler corticosteroid devices play a crucial role in treating these diseases by delivering anti-inflammatory medicine directly to the lungs to decrease inflammation and enhance breathing. For example, England noted 854,922 emergency hospital admissions for respiratory diseases during the financial year ending in 2024, as reported in June 2025 by the Office for Health Improvement and Disparities, a UK government department. This figure corresponds to a rate of 1,428 (ranging from 1,424 to 1,432) per 100,000 population, representing a 7% increase compared to the previous year. Hence, the upsurge in respiratory diseases' incidence drives the inhaler corticosteroid device market's growth.

Get Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25794&type=smp

What Are the Primary Segments Covered in the Global Inhaler Corticosteroid Device Market Report?
The inhaler corticosteroid device market covered in this report is segmented -

1) By Product Type: Metered-Dose Inhalers, Dry Powder Inhalers, Soft Mist Inhalers
2) By Formulation Type: Fluticasone Propionate, Budesonide, Beclomethasone, Mometasone Furoate
3) By Distribution Channel: Online Pharmacies, Retail Pharmacies, Direct Sales, Hospital Pharmacies
4) By Application: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Other Applications
5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:
1) By Metered-Dose Inhalers: Conventional Metered-Dose Inhalers, Breath-Actuated Metered-Dose Inhalers, Spacer-Integrated Metered-Dose Inhalers
2) By Dry Powder Inhalers: Single-Dose Dry Powder Inhalers, Multi-Dose Dry Powder Inhalers, Reservoir Dry Powder Inhalers
3) By Soft Mist Inhalers: Manual Soft Mist Inhalers, Battery-Operated Soft Mist Inhalers

What Are the Top Growth Trends in the Inhaler Corticosteroid Device Market?
Leading businesses in the inhaler corticosteroid device market are shifting their focus to providing innovative solutions such as combined rescue inhalers of albuterol and budesonide. This shift aims to increase the effectiveness of treatment and provide dual-action therapy with a single device, making it more convenient for patients. An inhaler combining these two compounds brings together a bronchodilator (albuterol) to open airways promptly and a corticosteroid (budesonide) to mitigate inflammation. This combination offers quick symptomatic relief and long-term asthma control in one device. A perfect example of this innovation is AstraZeneca PLC, a UK pharmaceutical company that, in January 2024, launched AIRSUPRA - the first and only FDA-approved rescue inhaler combining albuterol and budesonide. Tailored for as-needed usage to alleviate acute bronchoconstriction symptoms and minimize airway inflammation, AIRSUPRA can significantly decrease the chances of severe asthma attacks. This unique approach, which brings together a short-acting beta2-agonist (albuterol) with an inhaled corticosteroid (budesonide) in one inhaler, has been approved by backing clinical trials that showcase its advantage over using albuterol alone in preventing asthma attacks.

Customize Your Insights And Get The Full Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25794&type=smp

Which Companies Are Shaping the Future of the Inhaler Corticosteroid Device Market?
Major companies operating in the inhaler corticosteroid device market are AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Teijin Pharma Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Chiesi Farmaceutici S.p.A., Cipla Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Mundipharma International Limited, Lupin Limited, Zydus Lifesciences Limited, Recipharm AB, Glenmark Pharmaceuticals Limited, Orion Corporation, Beximco Pharmaceuticals Limited, PARI Medical Holding GmbH, Kos Pharmaceuticals Inc.

Which Region Holds the Largest Market Share in the Inhaler Corticosteroid Device Industry?
North America was the largest region in the inhaler corticosteroid device market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inhaler corticosteroid device market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Reach Out to Us
Speak With Our Expert:Saumya Sahay,
Americas +1 310-496-7795,
Asia +44 7882 955267 & +91 8897263534,
Europe +44 7882 955267,
Email: saumyas@tbrc.info
The Business Research Company - www.thebusinessresearchcompany.com
Follow Us On:LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.